Figure 4 | Scientific Reports

Figure 4

From: Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

Figure 4

PD-1+ lymphocytes are increased in PBMCs from GEP-NET patients with progressive disease. PBMCs from 32 patients and 32 controls were isolated and incubated with conjugated antibodies directed against CD3, CD4, CD8, CD25, FOXP3 and PD-1. Measurements were made by flow cytometry as stated in ‘Materials and Methods’ and values represent percentage of positive cells for each marker depicted as boxplots. (a–d) Percentage of PD-1+ cells in healthy controls and patients. (e–h) Percentage of PD-1+ cells in controls and patients classified according to disease status in non-residual disease (ND), stable disease (SD) or progressive disease (PD). Asterisks indicate significant differences (p-values for Tukey’s test: *p < 0.05, **p < 0.01, ***p < 0.001).

Back to article page